AcquisitionJul 22, 2026Completed
🇺🇸 United States
BSBioLife Solutions, Inc.RRepligen Corporation
Healthcare › Medical Devices
Enterprise value$1.5BEnterprise value
AnnouncedJul 22, 2026
ConsiderationCash and stock
StructureOne-step merger
RegionNorth America
Cross-borderNo
Contingent paymentNo
Overview
Repligen agreed to acquire BioLife Solutions under a definitive merger agreement for an enterprise value of about $1.5 billion, with BioLife holders receiving $11.25 in cash and 0.1442 Repligen shares per share ($31.00 total value).
Deal rationale
The deal expands Repligen's presence in the high-growth cell therapy market by adding BioLife's market-leading biopreservation media and high-margin recurring revenue business.
AI-generated from the SEC filingCompletedHealthcare › Medical DevicesUnited StatesNorth America
Timeline
Valuation and terms
| Equity value | Undisclosed | |
|---|---|---|
| Enterprise value | $1.5B | Headline figure |
| Consideration | Cash and stock |
Advisors
Buy-side
GSGoldman SachsPWPerella Weinberg Partners
Sell-side
CPCenterview Partners